#ESMO26: Akeso details ivonescimab's biliary cancer success, drawing Keytruda comparisons
MADRID — Akeso on Sunday spelled out by how much its Summit Therapeutics-partnered PD-1xVEGF bispecific improved survival in a late-stage, China-only biliary tract cancer study, in one of its early moves to find success beyond ...
We haven't written up this one. Endpoints News has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.